Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma

Inclusion Criteria: * Histologically proven melanoma * For subjects with brain metastases that require radiation, therapy must have been completed at least 4 weeks prior to Day 1 of Study Drug * Have unresectable melanoma with measurable metastases * Be a minimum of 4 weeks since prior surgical resection or major surgical procedure and a minimum of 2 weeks since chemotherapy/ biochemotherapy * Performance score of Karnofsky ≥ 60%, or Eastern Cooperative Oncology Group (ECOG) ≤ 2, or WHO ≤ 2 * If steroids are needed, be on a stable or decreasing dose of steroids for at least 1 week Exclusion Criteria: * Hypersensitivity to Cremophor EL * Have current/active intratumor hemorrhage by CT/MRI within 3 weeks prior to Day 1 of Study Drug confirmed by CT/MRI * Have ocular melanoma * Have primary intradural melanoma or leptomeningeal involvement * Have cardiovascular disease (unstable angina or MI) * Have cerebrovascular disease (stroke and/or TIA) * Have uncontrolled hypertension * Have a cardiac ejection fraction \< 50% * Have Troponin-I elevated above the normal range